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Accepted 2 August 2013AbstractObjective: The incidence of port site metastasis after robotic-assisted laparoscopic surgery for cervical cancer is not well known. According to
recent studies of gynecological malignancies, the reported incidence is low and comparable to the results of conventional laparoscopic surgery.
Here, we report the case of a patient who suffered port site metastasis after robotic-assisted laparoscopic hysterectomy for stage IB1 uterine
cervical cancer.
Case report: The current case is, as we know, only the third episode of port site metastasis after robotic-assisted laparoscopic surgery for cervical
cancer documented in the medical literature. Following diagnosis of the port site metastasis, the patient was treated with concurrent chemo-
radiotherapy (CRT) and experienced a remarkable early response. We reviewed the patient’s medical chart and imaging studies, and searched the
Medline database to evaluate the incidence, prognosis and treatment outcomes of such cases of port site metastasis in uterine cervical cancer
patients.
Conclusion: CRT resulted in a rapid decrease in tumor size and relief of abdominal pain in our patient. CRT might be considered as a salvage or
palliative modality in patients with port site metastasis and/or locoregional recurrence.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Laparoscopic surgery is widely used for the treatment of
benign disease entities, and is also applied for selected cases
of malignancy. Robotic-assisted laparoscopic surgery (RALS)
is increasingly replacing traditional laparoscopic surgery
because of its advantages such as high-resolution three-
dimensional imaging and the ability to apply more physio-
logical, wrist-like movements to the maneuvering of surgical
instruments, resulting in finer control of critical movements* Corresponding author. Department of Radiation Oncology, Samsung
Medical Center, Sungkyunkwan University School of Medicine, #50 Ilwon-
dong, Kangnam-ku, Seoul 135 710, South Korea.
E-mail address: sjhuh5201@gmail.com (S.J. Huh).
1028-4559/$ - see front matter Copyright  2013, Taiwan Association of Obstetri
http://dx.doi.org/10.1016/j.tjog.2013.10.018[1]. The da Vinci robotic system (Intuitive Surgical, Sunny-
vale, CA, USA) is increasingly being utilized in the field of
gynecological oncology. Such new techniques, however, have
significant learning curves and the results depend on the in-
dividual surgeon’s skill. Several recent reports have shown that
RALS requires longer operation times, leads to greater blood
loss, and results in higher operative complication rates
compared to traditional laparoscopic surgery [2].
When using minimally invasive surgical techniques such as
laparoscopic surgery or RALS, trocars are placed in port sites.
These port sites may become implantation hubs for tumor cells
as they are manipulated during surgery. Such port site me-
tastases are not common, but are more frequently reported
after laparoscopic surgery for the treatment of gallbladder
adenocarcinoma [3]. Port site metastases occur in 1e2% ofcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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commonly reported in cases of ovary, fallopian tube, or
endometrial carcinomas [4,5]. For uterine cervical cancer, a
study of 921 patients reported a rate of port site metastasis of
0.43%, and the incidence was lower than that of ovarian or
fallopian tube carcinomas [6]. However, in small, institution-
based studies of 160 and 75 patients, the rates of port site
metastasis were reported as 1.25% and 1.3%, respectively
[5,7]. For patients treated with RALS for uterine cervical
cancer, as far we know, there have been only two reported
cases of port site metastasis.
We recently encountered port site metastasis in a young
patient with early stage (IB1) uterine cervical cancer after
robotic-assisted laparoscopic radical hysterectomy, right
salpingo-oophorectomy, and pelvic lymphadenectomy. We
report here the details of this rare case accompanied by a
review of prior studies of port site metastasis after mini-
mally invasive surgery for the treatment of uterine cervical
cancer.Fig. 1. (A) Before chemoradiotherapy. (A-1) A 7.2-cm abdominal wall mass was d
(A-2) The abdominal mass showed markedly increased 18F-fluorodeoxyglucose (FD
also increased uptake in several pelvic lymph nodes and in the pelvic peritoneum. (
wall mass decreased rapidly. (B-2) The abdominal wall mass showed markedly
radiotherapy. (C-1) There was a 1e1.5-cm fibrotic mass found on magnetic resona
residual lesion showed markedly decreased 18F-FDG uptake (SUVmax ¼ 2.3).Case report
A 35-year-old woman was referred to Samsung Medical
Center due to abnormal cytological findings on a Papanicolaou
smear performed for routine surveillance. On gynecological
examination, a 1.5-cm pinkish mass was visualized at the two
o’clock position. A punch biopsy revealed endocervical
glandular atypia suggestive of endocervical adenocarcinoma.
For staging work-ups, complete blood count, blood chemistry,
chest X-ray, computed tomography (CT) of the abdomen and
pelvis, cystoscopy, and sigmoidoscopy were performed. Pelvic
magnetic resonance imaging (MRI) scanning and 18F-fluo-
rodeoxyglucse (FDG) positron emission tomography (PET/
CT) were also performed. The patient was diagnosed with
stage IB1 cervical cancer and sent for surgery considering her
young age, and for functional preservation of the ovary.
In June 2011, the patient underwent robotic-assisted (da
Vinci Surgical System) laparoscopic radical hysterectomy,
right salpingo-oophorectomy, and pelvic lymphadenectomy.etected at the right lower quadrant trocar site on magnetic resonance imaging.
G) uptake [maximum standardized uptake value (SUVmax)¼ 19.4]. There was
B) During chemoradiotherapy (after 30.6 Gy). (B-1) The size of the abdominal
decreased 18F-FDG uptake (SUVmax ¼ 5.0). (C) One month after chemo-
nce imaging. There was no detectable peritoneal or pelvic disease. (C-2) The
Fig. 2. Radiotherapy. Three-dimensional conformal radiotherapy was planned
to cover the clinical target volume (sky blue line) by 97% isodose lines. (A)
The initial radiation field included the abdominal wall mass (port site
metastasis) and pelvic disease. (B) The boost volume included the residual
abdominal wall mass, and mapping was generated using new computed to-
mography planning.
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incision down to the abdominal wall fascia, and pneumo-
peritoneum was established with CO2 gas injected through a
Veress needle. The remaining four trocars were placed without
difficulty in the right lower quadrant (RLQ, 8 mm), left lower
quadrant (8 mm), right upper quadrant (8 mm) and mid-upper
abdomen (11 mm). In the RLQ port, a trocar was inserted
through the patient’s prior appendectomy scar. There were no
enlarged pelvic lymph nodes or ascites. Histopathological
examination revealed a poorly differentiated 1 cm  0.8 cm
mucinous adenocarcinoma of the cervix with an invasion
depth of 6 mm. The tumor was confined within the uterine
cervix and all of the resection margins were negative. There
were no involved pelvic lymph nodes. She did not receive any
adjuvant therapy.
Four months after robotic surgery, the patient experienced
abdominal pain. Five months after surgery, she complained of
abdominal swelling. CT scans of the abdomen and pelvis and
PET/CT scans revealed multiple hypermetabolic masses in the
right lower abdominalwall at theRLQport site, lower peritoneal
cavities, and bilateral iliac lymph nodes (Fig. 1A1 and A2). On
ultrasonography-guided core-needle biopsy, the mass in the
abdominal wall showed poorly differentiated adenocarcinoma.
From January to February 2012, the patient underwent con-
current chemoradiotherapy (CCRT). The chemotherapeutic
regimen consisted of five cycles of weekly cisplatin (40mg/m2).
The initial field of irradiation covered the pelvis, including the
pelvic peritoneal seeding, hypermetabolic pelvic lymph nodes,
and the abdominal wall mass (Fig. 2A). A total radiation dose of
50.4 Gy was delivered using three-dimensional conformal
radiotherapy in 1.8-Gy fractions. After the initial dose of
50.4 Gy, a boost dose of 10.8 Gywas delivered in six fractions to
the abdominal wall mass based on the second simulation CT
shown in Fig. 2B. During CCRT, the patient complained of mild
nausea, vomiting, and intermittent diarrhea, but all of her
adverse symptoms were manageable with oral medications.
There was no interruption of CRT. During the treatment, the
abdominal wall mass shrank rapidly, and at the end of CCRT,
therewas no palpablemass. 18F-FDGPET/CT showed amarked
decrease in size and metabolic activities of the abdominal and
pelvic disease during CCRT (Fig. 1B1 and B2).
One month after completion of CCRT, the patient did not
complain of any discomfort. On physical examination, there
was no palpable mass and the only demonstrable adverse ef-
fect was skin pigmentation over the irradiated area. Pelvic
MRI showed no definite mass (Fig. 1C1), and 18F-FDG PET/
CT scan showed no increased uptake at the previously
observed sites. There was no evidence of newly developed
hypermetabolic sites (Fig. 1C2). At 17 months’ follow-up,
there was no evidence of locoregional recurrence or distant
metastasis.
Review of prior reports of port site metastases in uterine
cervical cancer
We searched the PubMed database from 1990 to 2012 for
other reports of port site metastasis after the minimallyinvasive surgery of uterine cervical cancer. We included both
traditional laparoscopic surgery and robotic-assisted laparo-
scopic surgery in order to evaluate possible mechanisms and
risk factors for port site metastasis.
Conclusion
Port site metastasis of cervical cancer is rare. Early data
suggest that most cases of port site metastasis after minimally
invasive surgery for the treatment of gynecological malig-
nancies occur in ovarian cancer patients. It is important to
recognize the fact that most of the data related to the port site
metastasis come from the cases of traditional laparoscopic
surgery, and not from RALS. It is mainly due to the more
recent application of robotic surgery in gynecological
malignancies.
There have been few reports of port site metastasis in
uterine cervical cancer. Our Medline search yielded 23 cases
of port site metastasis after laparoscopic surgery (including
diagnostic procedures) for cervical cancer published since
1990. Among these 23 cases, only six had isolated port site
metastasis of cervical cancer. In the remaining 17 cases, other
561B. Kim et al. / Taiwanese Journal of Obstetrics & Gynecology 52 (2013) 558e563recurrences in the abdomen/pelvis, peritoneal carcinomatosis,
and/or distant metastases accompanied the port site metastasis
(Table 1) [5e22].
In a study of 181 patients undergoing RALS for the treat-
ment of gynecological malignancies, Ndofor et al reported a
1.1% rate of port site metastasis. Fifty patients with stage I
cervical cancers were included in that study, but none suffered
from port site metastasis [23]. These rates of port site metas-
tasis after RALS for the treatment of gynecological malig-
nancies are similar to the rates of port site metastasis after
traditional laparoscopic surgery. Prior to the current study, as
far as we know, there were only two reports of port site
metastasis after RALS for the treatment of uterine cervical
cancer. Sert reported the first case of port site metastasis after a
robotic-assisted laparoscopic radical hysterectomy in a patient
with stage IB1 cervical adenocarcinoma. Interestingly, the
patient in that case sustained bladder damage during RALSTable 1
Port site metastasis after laparoscopic surgery for uterine cervical cancer.
Author Surgery Stage LN Removal
of disease
tissue
Retrieval
bag
Histology
Patsner [8] Diagnostic þ
biopsy
IB þ N N SQ
Naumann [9] Guide for
Syed implant
IIIB  N N SQ
Wang [10] H þ PND IB1 þ Y N SQ
Kadar [11] PAPND IB2 þ Y N SQ
PAND IIIB þ Y N SQ
Lavie [12] H þ BSO þ
PND
IA  N N AD, PD
Lane [13] PAPND IB1 þ Y N AD,SQ
Carvalho [14] PND IB2 þ Y nr SQ
Lecuru [15] PND IB1  N Y SQ
Kohlberger
[16]
Diagnostic IB1  N
(Biopsy)
N SQ
Doret [17] LND þ TOB IIB  N N Small
Gregor [18] PND IIB þ Y N SQ
Agostini [19] PAND IIB þ Y N SQ
Tjalma [20] PAND IIIB  N nr SQ
Martinez-
Palones [21]
RH þ PAPND IIIB þ Y Y AD, PD
Park [7] PAPND IIB þ Y Y AD
Yenen [22] PAND IIB þ Y Y SQ
Zivanovic [5] Guide for
implant
IB  N Y SQ
LND IB þ Y Y SQ
Martinez [6] LND IB  N N SQ
PAND IIB þ Y nr SQ
PAND IIB þ Y nr SQ
RH þ PAPND IVA þ Y N AD
AD ¼ adenocarcinoma; BRT ¼ brachytherapy; BSO ¼ bilateral salpingo-ooph
DOD ¼ dead of disease; e ¼ extraction port; ERT ¼ external beam radiotherapy;
dissection; mets ¼ metastasis; N ¼ none; ne ¼ non-extraction port; NED ¼ no e
PAPND ¼ para-aortic and pelvic node dissection; PC ¼ peritoneal carcinomatos
recurrence; RH ¼ radical hysterectomy; SQ ¼ squamous; TOB ¼ transposition oand experienced recurrence in the bladder in addition to the
port-site metastasis [24]. Including our case, all three patients
with port site metastasis after RALS for the treatment of
cervical cancer had early stage disease and the port site
metastasis was combined with other failures such as peritoneal
carcinomatosis or pelvic node metastasis (Table 2) [24,25].
Only two relevant case reports have been published in the
medical literature, therefore, the incidence of port site
metastasis after RALS of cervical cancer remains unknown.
Achieving a better understanding of port site metastasis is
critical to prevent and predict such failures. However, the
mechanism of port site metastasis has not been defined.
Several possible mechanisms have been postulated, including
hematogeneous spread, direct wound implantation during
extraction of the malignant specimen or through a contami-
nated instrument, chimney effect, aerosolization of tumor
cells, surgical techniques such as excessive tumorPort
site
mets
(mo)
Location Concomitant
failure
Treatment Outcome
5 Umbilicus (ne) PR CTX DOD 9 mo
5 Umbilical (ne) PC, RP LNs
and liver mets
Palliative DOD 3 wks
2 Multiple PC CTX DOD 5 mo
Nr Lat (ne) PR Nr DOD 24 mo
nr Lat (ne) PR nr DOD 4 mo
9 Lat (e) N EXC nr
10 Lat (e) N EXC NED 19 mo
1.5 All ports PC and Pelvic LNs nr nr
48 Umbilicus (ne) N EXC þ ERT Lung mets
7 mo
19 Suprapubic (ne) N EXC þ BRT þ
CCRT (ERT)
NED 49 mo
6 Lat (nr) N EXC þ ERT,
CTX
NED 54 mo
3 Lat (e) N EXC nr
7 Lat (e) PC EXC DOD 14 mo
15 Umbilical (ne) Para-arotic
and liver mets
EXC þ CTX DOD 24 mo
7 Umbilical Cerivical
progression
EXC nr
1 Umbilical,
Both lat
Liver mets CTX DOD
12 Lat (ne) Vaginal recurrence CTX þ EXC nr
6.3 nr Bladder and
vaginal recurrence
nr DOD 12 mo
5.8 nr PC nr DOD 9 mo
25 Umbilical (e) Vaginal recurrence EXC þ ERT DOD 30 mo
6 Lat PC CTX DOD 7 mo
8 Lat PC CTX DOD 26 mo
8 Lat (ne) Pelvic LNs EXC DOD 28 mo
orectomy; CCRT ¼ concurrent chemoradiotherapy; CTX ¼ chemotherapy;
EXC ¼ excision; H ¼ hysterectomy; Lat ¼ lateral port; LND ¼ lymph node
vidence of disease; nr ¼ not reported; PAND ¼ para-aortic node dissection;
is; PD ¼ poorly differentiated; PND ¼ pelvic node dissection; PR ¼ pelvic
f bilateral ovaries.
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pneumoperitoneum, the effect of CO2 on tumor cell biology,
and impairment of local immune response after laparoscopic
surgery [26]. Wilkinson et al studied an in vivo model of port
site metastasis by comparing a laparoscopic port site with an
open incision. There was no significant difference in the in-
cidences of port site metastasis between open incision and
laparoscopic video port site. Recurrences, however, occurred
more frequently at the sites of laparoscopic working ports
compared to the sites of open wounds or laparoscopic video
ports. This result supports the possibility of direct seeding to
port sites by surgical instrumentation or contamination with
viable tumor cells [27], and might explain a large portion of
port site metastases. Port site metastases, however, have been
reported in patients who underwent diagnostic laparoscopy
without manipulation of the tumor and even in patients
without abdominal disease [5,6,9,12,15e17,20]. Moreover,
some patients have experienced other scar site metastases in-
dependent of port sites [28]. These reports suggest that port
site metastasis can occur through multiple, complex mecha-
nisms. The reported incidence of port site metastasis varies
depending on the primary tumor sites, and gallbladder
adenocarcinoma is a well-known primary cancer of port site
metastasis. Therefore, there may be inherent characteristics of
tumor cells that make metastasis to ports or wounds more
likely, especially as they relate to the patient’s immune reac-
tion after surgery.
Considering the higher probability of port site metastasis by
direct tumor implantation [27], it is essential to minimize the
spread of malignant cells during surgery. Several measures to
prevent the spread of malignant cells during surgery have been
proposed and include proper placement of trocars with mini-
mal tissue trauma, rinsing trocars in 5% povidineeiodine
before insertion, trocar fixation and prevention of gas leakage,
minimal removal and reintroduction of trocars during the
procedure, rinsing the tip of instruments in 5% povidineeio-
dine when changing instruments, minimal handling of the
tumor, deflating the pneumoperitoneum with trocars in place,
the use of protective bags to retrieve the tumor, removing all
intra-abdominal fluid before trocar removal, irrigating the sites
of the trocars with 5% povidineeiodine, and closure of
10e12-mm trocar sites [4]. In some studies, peritoneal and/or
port site irrigation with cytotoxic agents was proposed to
reduce port site metastasis [6].
RALS is generally considered less cost-effective, and it
usually takes more time, than traditional laparoscopic or open
surgery [2]. The cost-effectiveness of RALS largely depends on
the status of the patient, the status of their disease, and the sur-
geon’s skill. Longer proceduresmay increase the risk of port site
metastasis by allowing more time for tumor cells to be shed and
seed the port sites. The comparative effectiveness and safety of
RALS should be verified before broader application especially
in malignancies.
Port site metastasis is generally considered a poor prog-
nostic factor. Patients with port site metastases usually have
other synchronous metastases. However, there are no general
recommendations for treatment of port site metastasis, perhaps
563B. Kim et al. / Taiwanese Journal of Obstetrics & Gynecology 52 (2013) 558e563due to the heterogeneity and rarity of port site metastasis. If it
is surgically resectable, excision of the port site metastasis is
generally recommended. If the mass is not resectable, the
patient might be treated with supportive care, chemotherapy,
and/or radiotherapy. There are several reports of cervical
cancer patients who suffered from port site metastasis and
underwent radiotherapy (Tables 1 and 2). Brachytherapy and/
or external beam radiotherapy have been attempted, but there
are no reports describing the response to radiotherapy. Our
patient was treated with CCRT and experienced prompt relief
from pain and rapid shrinkage of tumors, as well as metabolic
complete remission at short-term follow-up. She remained
disease-free at 17 months’ follow-up without specific com-
plications. More follow-up is needed, but radiotherapy and/or
chemotherapy might be considered as a potentially effective
treatment modality for port site metastases after minimally
invasive surgery, especially in cases in which recurrence is
confined to the abdomen and pelvis.
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